Hematology

This collection features hematologists and oncologists discussing blood disease, with a strong focus on multiple myeloma: gene expression and intraclonal heterogeneity, bone marrow microenvironment, stem cell transplantation, and CAR T-cell therapy.

Patients and families most often ask: What do genetic features of this specific myeloma, such as intraclonal heterogeneity, mean for the treatment choice? Is stem cell transplantation still the right option for this patient, or has a newer treatment approach overtaken it? Is CAR T-cell therapy realistically available and appropriate for this particular case? What should a patient with multiple myeloma be asking about immunization, bone health, and quality of life during treatment?

Multiple myeloma treatment is advancing quickly, and access to newer options such as CAR T-cell therapy differs between centers and countries. An independent panel of academic hematologists, matched to this exact disease, can review a specific case against the most current evidence and the realistic treatment sequence available in different countries and health systems today, before a plan is finalized.

To have a blood disease case reviewed this way, see the medical second opinion page.